/ Print /


Opinion: The Bad Politics of Carving-Out Medicaid Managed Care DrugsAbout half of states have transitioned at least some Medicaid beneficiaries away from fee-for-service (FFS) drug programs into drug plans integrated with managed care. Our policy analyst shares why he believes more should do so.
What Roche’s Purchase of Flatiron Health Means for Health ExecsSwitzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.
Report Slams 340B Drug Discount ProgramA Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.
Will biosimilars deliver on expectations?
Will biosimilars deliver on expectations?This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
Four health programs successfully fight the opioid epidemicShocking opioid overdose statistics make it crucial to address the epidemic. Here are four programs to watch
Opioid crisis legal ramifications: How to protect your healthcare organizationOverprescribing by just one practitioner can lead to an untoward outcome that may readily affect the entire healthcare facility.
Four healthcare policy changes to watch in 2018
Four healthcare policy changes to watch in 2018Insiders unmask what policy actions will continue and what will develop in the next year.
Is there a simple fix for the Part D discount program?A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
Top 2018 challenges healthcare executives face
Top 2018 challenges healthcare executives faceExperts weigh in on the findings from Managed Healtcare Executive’s 2017 State of the Industry Survey.
CMS plan to slash 340B payments under fire by hospitalsHere are four ways CMS’ final rule related to the 340B Drug Pricing Program could affect the healthcare industry.